Oral Medication | Page 9 of 11

Diabetes Drug Maker Hid Study Data

Avandia Safety Questioned: The New York Times reports that diabetes drug maker SmithKline did not reveal the results of a study showing its drug Avandia was riskier to the heart than a competing drug, Actos. The New York Times states, "instead of publishing the results, the company spent the next 11 years trying to cover them up, according to documents recently obtained by The New York Times. The company did not ...

Avandia Recall Possible: FDA Reviews

The diabetes drug, Avandia, may be more dangerous than was previously reported. According to CNN, a review of Avandia released last week by the FDA states that officials overseeing GlaxoSmithKline Plc’s RECORD study repeatedly submitted sloppy data and failed to follow up on reports of problems in patients -- including reports of patient deaths...

Type 2 Diabetics May be Able to Tolerate Higher Doses of Metformin Using Glumetza

A press release issued today by Depomed, Inc. and Santarus, Inc says that according to the clinical trial results, patients previously intolerant of metformin may be able to tolerate higher efficacious doses of metformin when treated with GLUMETZA, with fewer gastrointestinal side effects. GLUMETZA is a once-daily, extended release formulation of metformin, and is approved for use in adults with type 2 diabetes...

Bristol-Myers Squibbs’ Dapagliflozin Demonstrated Improved Glycemic Control in Adults with Type 2 Diabetes

Bristol-Myers announced that findings from a 24-week Phase 3 clinical study, published online in the latest issue of Diabetes Care, demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of HbA1c levels...

Depomed Recalls Type 2 Diabetes Drug Glumetza

Drug developer Depomed Inc announced it would recall 52 lots of its type 2 diabetes drug Glumetza due to the presence of traces of a certain chemical in the tablet's 500 mg bottle, according to a Reuters report...

Type 2 Diabetes May Be Prevented With a Combination of Avandia and Metformin

According to a new report published in the Lancet, taking a low dose of GlaxoSmithKline's diabetes drug Avandia (rosiglitazone) combined with metformin was highly effective in prevention of type 2 diabetes in patients with impaired glucose tolerance, with little effect on the clinically relevant adverse events of these two drugs. The study included 207 patients with impaired glucose...

GlaxoSmithKline Settles More Avandia Lawsuits

GlaxoSmithKline Plc has settled thousands more lawsuits brought by patients alleging its Avandia diabetes drug caused heart attacks, in a move that may defuse potentially massive claims over the medicine. According to a Reuters report, a spokeswoman for Glaxo said that consolidated cases which had been due to come to court...

Diabetes Drug Metformin Linked to Vitamin B 12 Deficiency

Diabetics treated over long periods with the drug metformin, one of the most commonly prescribed drugs for the treatment of diabetes, are at risk of developing vitamin B12 deficiency. This condition is likely to get worse over time, according to a study published in the British Medical Journal...

Avandia Settlements: Glaxo Agrees to Pay $60 Million

GlaxoSmithKline Plc agreed to pay about $60 million in the first settlements of lawsuits alleging the company’s Avandia diabetes drug causes heart attacks and strokes in some users, according to a Bloomberg report...

Superior Efficacy of Victoza Compared to Januvia in the Treatment of Type 2 Diabetes

Novo Nordisk's new diabetes drug Victoza proved more effective than Merck & Co's Januvia in a head-to-head study published, in the Lancet. The 26-week trial showed that Victoza produced significantly greater reductions in HbA1C, fasting plasma glucose and body weight than Januvia, with similar or better overall treatment satisfaction....